These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30413150)

  • 1. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015).
    Park H; Liu X; Henry L; Harman J; Ross EA
    BMC Nephrol; 2018 Nov; 19(1):318. PubMed ID: 30413150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.
    Thamer M; Zhang Y; Kshirsagar O; Cotter DJ; Kaufman JS
    Am J Kidney Dis; 2014 Nov; 64(5):706-13. PubMed ID: 25011692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States.
    St Peter WL; Guo H; Kabadi S; Gilbertson DT; Peng Y; Pendergraft T; Li S
    BMC Nephrol; 2018 Mar; 19(1):67. PubMed ID: 29544446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
    Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
    JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
    Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
    J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis.
    Kuo KL; Hung SC; Liu JS; Chang YK; Hsu CC; Tarng DC
    Nephrol Dial Transplant; 2015 Sep; 30(9):1518-25. PubMed ID: 25829323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
    Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
    Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion burden among patients with chronic kidney disease and anemia.
    Lawler EV; Bradbury BD; Fonda JR; Gaziano JM; Gagnon DR
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):667-72. PubMed ID: 20299366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.
    Galle JC; Addison J; Suranyi MG; Claes K; Di Giulio S; Guerin A; Herlitz H; Kiss I; Farouk M; Manamley N; Wirnsberger G; Winearls C
    Nephrol Dial Transplant; 2016 Dec; 31(12):2073-2085. PubMed ID: 27190334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD.
    Toto R; Petersen J; Berns JS; Lewis EF; Tran Q; Weir MR
    J Am Soc Nephrol; 2021 Feb; 32(2):469-478. PubMed ID: 33288629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective database analysis of erythropoiesis-stimulating agent treatment patterns and associated healthcare resource use in patients with non-dialysis-dependent chronic kidney disease-related anaemia in Japan.
    Mishina S; Waratani M; Onozawa S; Okumura H; Ito Y; Yasuda Y
    Nephrology (Carlton); 2023 Aug; 28(8):446-455. PubMed ID: 37161826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
    Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
    Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.
    Gauthier-Loiselle M; Michalopoulos SN; Cloutier M; Serra E; Bungay R; Szabo E; Guérin A
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1703-1713. PubMed ID: 34818094
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence, incidence, and treatment of anaemia in patients with non-dialysis-dependent chronic kidney disease: findings from a retrospective real-world study in Italy.
    Minutolo R; Grandaliano G; Di Rienzo P; Snijder R; Degli Esposti L; Perrone V; Todorova L
    J Nephrol; 2023 Mar; 36(2):347-357. PubMed ID: 36370331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.